KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Liabilities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Total Liabilities for 15 consecutive years, with $390.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 17.63% to $390.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $390.9 million, a 17.63% increase, with the full-year FY2025 number at $390.9 million, up 17.63% from a year prior.
  • Total Liabilities was $390.9 million for Q4 2025 at Supernus Pharmaceuticals, up from $370.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $879.7 million in Q1 2023 to a low of -$828.4 million in Q1 2022.
  • A 5-year average of $488.6 million and a median of $374.9 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 210.02% in 2022, then surged 206.18% in 2023.
  • Supernus Pharmaceuticals' Total Liabilities stood at $873.3 million in 2021, then dropped by 6.53% to $816.3 million in 2022, then tumbled by 56.37% to $356.2 million in 2023, then fell by 6.69% to $332.3 million in 2024, then rose by 17.63% to $390.9 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Total Liabilities are $390.9 million (Q4 2025), $370.1 million (Q3 2025), and $318.5 million (Q2 2025).